Vaccine venture: US pharmaceutical giant Merck and the UK's Wellcome Trust have launched a joint not-for-profit £90-million (US$150-million) medical research centre in India to develop affordable vaccines for neglected diseases. This is the first time that a pharmaceutical company and a major medical research charity have entered into a bilateral partnership to create vaccines aimed at lowincome countries. For more, see page 323. Backed by a feed-in tariff that will guarantee long-term electricity sales, First Solar, based in Tempe, Arizona, plans to install thin-film panels that have a total generating capacity of 2,000 megawatts in Ordos City by 2019. First Solar also agreed to explore the possibility of building manufacturing sites in Ordos and expanding other operations in China.
• POLICY Osiris Therapeutics of Columbia, Maryland, saw its share price plummet on 8 September (see chart) after announcing that its stem-cell therapy had failed late-stage clinical trials. Prochymal, which consists of cultured mesenchymal stem cells taken from bone marrow, was no better than a placebo at subduing graft-versus-host disease -a potentially fatal complication in bonemarrow transplants in which immune cells from the donated marrow attack the recipient. "I do think it's a blow to the stem-cell community," says Edward Tenthoff, an analyst at Piper Jaffray in New York. The good news, he says, is that "it's a failed trial, not a safety concern". Last month, biopharmaceutical firm Geron, of Menlo Park, California, had to delay its trial of embryonic-stem-cell therapy for spinalcord injury for a second time after animal data revealed microscopic cysts growing around the injury site.
Researchers think that mesenchymal stem cells could still be an effective way to treat some patients. "Even though it seems to the business world to be a setback, I think [researchers] can learn and go on," says Pranela Rameshwar, a stem-cell scientist at New Jersey Medical School in Newark.
Shares in various other stem-cell companies were unaffected by the Osiris trial results.
For more, see http://tinyurl.com/m8976j
• RESEARCH
Researcher arrest: A senior scientist at RIKEN, Japan's premier research institute, was arrested last week for allegedly misappropriating research funds. Tatsuo Wada, who studies the behaviour of supramolecular assemblies of organic molecules, allegedly placed fictitious orders worth ¥11.7 million (US$128,000) from RIKEN to Akiba Sangyo, a Tokyo-based company that distributes scientific equipment. The company's president, Etsuo Kato, was also arrested, and RIKEN has begun legal proceedings against Wada to recover the funds. For more, see page 327.
Brain drain:
The immediate dismissal of 200 scientists from an Israeli government programme that provides jobs for high-level immigrant scientists was averted last week -but the future of the $40-milliona-year programme remains in doubt. Protests by scientists and universities led to a cabinet decision to restore 2009 funding for the KAMEA programme,
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London's Natural History Museum opened a £78-million (US$130-million) Darwin Centre to the public on 15 September. Its Cocoon building houses a space for visitors to peer at scientists in the lab.
• EVENTS Agronomist dies: Norman Borlaug, who won the 1970 Nobel peace prize for his role in tackling world hunger, died on 12 September aged 95. Borlaug developed high-yield, disease-resistant wheat, kickstarting the "green revolution" in the 1960s, which dramatically increased food production in the developing world. He was a distinguished professor at Texas A&M University, in College Station. A full obituary will appear in a forthcoming issue.
• AWARDS Publication policy: Members of the National Academy of Sciences will from July 2010 no longer be able to communicate work by a non-member for publication in the Proceedings of the National Academy of Sciences, the journal announced last week. Instead, non-members must submit papers directly to the journal for peer review, although they may ask an academy member to edit their paper first.
which pays the base salaries of around 500 scientists who have emigrated to Israel, mainly from the former Soviet Union. Entrance to the programme has been frozen and further changes are under consideration. For more, see http://tinyurl.com/ news-2009-912 working more than a month ago. The Heterodyne Instrument for the Far Infrared (HIFI), performs high-resolution infrared spectroscopy and is intended to detect elements in gas clouds swirling in starforming regions. HIFI's project leader, Peter Roelfsema, says he is confident it will be switched on again, but doesn't yet know what caused the instrument's shutdown. For more, see http:// tinyurl.com/r2l35t
